

What Can Change my Practice After Evaluate Progress that I Heard at the Meeting of the ASCO 2017?

Adrian Pablo Hunis*

¹Board Certified in Medical Oncology, School of Medicine University of Buenos Aires, Argentina

²Carrer Specialist in Oncology, School of Medicine

³University of Buenos Aires (UBA), Argentina

⁴Head Professor of Oncology, Maimonides University, Argentina

Received date: 12/15/2017 Accepted date: 12/20/2017 Published date: 12/20/2017

*Corresponding author: adrian.hunis@uba.edu.ar

Copyright: © Hunis AP. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Breast cancer is the leading cause of cancer death among women worldwide. The aim of this study was to evaluate the impact of the ASCO 2017 meeting on the practice of breast cancer treatment. A survey was conducted among oncologists, and the results showed that the majority of respondents reported changes in their practice, including the use of targeted therapy and immunotherapy. The most significant changes were in the use of trastuzumab and pembrolizumab. The results of this study suggest that the ASCO 2017 meeting had a significant impact on the practice of breast cancer treatment.

Breast cancer

Breast cancer is the leading cause of cancer death among women worldwide. The aim of this study was to evaluate the impact of the ASCO 2017 meeting on the practice of breast cancer treatment. A survey was conducted among oncologists, and the results showed that the majority of respondents reported changes in their practice, including the use of targeted therapy and immunotherapy. The most significant changes were in the use of trastuzumab and pembrolizumab. The results of this study suggest that the ASCO 2017 meeting had a significant impact on the practice of breast cancer treatment.

Breast cancer is the leading cause of cancer death among women worldwide. The aim of this study was to evaluate the impact of the ASCO 2017 meeting on the practice of breast cancer treatment. A survey was conducted among oncologists, and the results showed that the majority of respondents reported changes in their practice, including the use of targeted therapy and immunotherapy. The most significant changes were in the use of trastuzumab and pembrolizumab. The results of this study suggest that the ASCO 2017 meeting had a significant impact on the practice of breast cancer treatment.

Breast cancer is the leading cause of cancer death among women worldwide. The aim of this study was to evaluate the impact of the ASCO 2017 meeting on the practice of breast cancer treatment. A survey was conducted among oncologists, and the results showed that the majority of respondents reported changes in their practice, including the use of targeted therapy and immunotherapy. The most significant changes were in the use of trastuzumab and pembrolizumab. The results of this study suggest that the ASCO 2017 meeting had a significant impact on the practice of breast cancer treatment.

Breast cancer is the leading cause of cancer death among women worldwide. The aim of this study was to evaluate the impact of the ASCO 2017 meeting on the practice of breast cancer treatment. A survey was conducted among oncologists, and the results showed that the majority of respondents reported changes in their practice, including the use of targeted therapy and immunotherapy. The most significant changes were in the use of trastuzumab and pembrolizumab. The results of this study suggest that the ASCO 2017 meeting had a significant impact on the practice of breast cancer treatment.

\Ugdçghj Y'DFY)a]bUfnXUUFYdfca]gbl[zk]h Ub Ubgk YfgcVWij Y Uci bX*Ş "

VYb' Uxá]b]gMYX hY Xfi [' UcbY Ubx]b' Wá V]bU]cb' k]h Ufrc']ri a U"

Targeted T erapies

ChYf' fyg' h' fYa Uf_WY]b' Hf[YX hYfU]Yg' kUg' hUhi cZ 'UchfY]b]VZk]h' Ubgk Yfg]b' +* dYfVbhcZdU]Yb]g% X] YfYbhlmdYg cZUj UbVXWbWf" YXfi [']gUgYWij Y]b\]V]cf' cZdfch]bg: i gcb _]bUgY fYWd]cf' hfcda]cgbUff _L Ubx \Ug UW]Y XZ]b' UXX]hcbz+ dYfVbhc cZ fYg]cbgYg' h' fYa U]b' hYj Y a cbhg' U Yf' hYUa Ybh]b]hU]cb"

-b' hY YXcZ]a a i bchYfUdnUfYUg' dYfYb]hXZ] cfUfYfYg']g fY]Uf]b[' hY Xfi fU]cb' cZ hY fYg]cbgY dYa Vfc']ri a U']b' bi a Yfci g h]Ug']b' g']X h a cfg" -b' UXX]hcbz hY Xfi [' \Ug' g' ckb']a dfcj YX g' fj]j U']b' Uj UbVX a YUca U Wá dUfYX' h' d'UWc' Ux Wá chYfUdnUg' gYbX']bY hYUa Yb]Zf' dU]Yb]g k]h' WfV]ca U i fch]U' Uj UbVXU Yf dfc] fYg]cb h' d'U]bi a "

Immunotherapy

-b']a a i bchYfUdnU g]i Xn]b' k \]W' \]Y dUf]V]UHX -bg]h hY fYg]UfWYg' cbW'c[m]JU' Yn < Yfcb' fj \]cL \ Ug' dfcj Yb' U]hVcXn V]cYg]YW' W' fc*-), *, , X]fYWX U]b]g]U]h[]b' 795 'Wá X Yj Yfm i gZ ']b' W'cb WbWf"

:]bU'na dYfYb]hX g]i X]Yg' k]h' fYZffUg' X' fUfY k]h' Wf]H']b dU]Yb]g k]h' a i]d'Y a nYca U fYZUf]m]b' fYU]gY Ubx cb' hY Y W]j Yb]g' cZ XUWá]h]V j Yfg g [Y]h]V Ubx UY]b]V j Yfg g W]r]h]b]V]b' i b[WbWf']b' i b[WbWf' bcb]ga U' W"

References

- % 5G7C YX W]cbU'Vcc_ "
- & 88% U]g]fUg'5G7C' 88% "

HfYUa Yb]h'c]bg'ga i]bYci g]m]c' h']g' dfc]h]b' f]hYg]bh]b' -) 1 ' cZ hYgY h a cfg' Ubx h' na d'c W]h]g' h']b' g]i X]Yg' d' Uj' 5 = Ubx =]X \ Ug